Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 older adults revaccination extension study
2020-000692-21Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GSK3003899A in respiratory syncytial virus disease (RSV), sponsored by GSK. Primary endpoint: Number of participants with solicited adverse events. Started Oct 2020; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-000692-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000692-21.